OBAT
OLEH:
NELLA NOVITA
2121012021
[1] Ataollahi, N., Broseghini, M., Ferreira, F. F., Susana, A., Pizzato, M., and Scardi, P. Effect of
High-Energy Milling on the Dissolution of Anti-HIV DrugEfavirenz in Different Solvents. ACS
Omega, Vol 6, (2021), p. 12647-12659.
[2] De Aquino, R. J. A., de Campos, L. M. M., Alves, R. J., Lages, G. P., and Pianetti, G. A.
Efavirenz related compounds preparation by hydrolysis procedure: Setting reference standards
for chromatographic purity analysis. J. Pharm. Biomed. Anal. (2007), 43, 298−303.
[3] Fandaruff, C., Rauber, G.S., Araya-Sibaja, A. M., Pereira, R.N., de Campos, C.E.M., Rocha,
H.V.A., Monti, G.A., Malaspina, T., Silva, M.A.S., Cuffini, S.L. Polymorphism of Anti-HIV
Drug Efavirenz: Investigations on Thermodynamic and Dissolution Properties. ACS Crystal
Growth & Design, (2014).
[4] Melo, A.C.C.D., Amorim, I.F.D.Cirqueira, M. D.L., and Martins, F.T. Toward novel solid-
state forms of the anti-HIV drug efavirenz: from low screening success to cocrystals engineering
strategies and discovery of a new polymorph. Crystal Growth & Design, (2013). DOI:
10.1021/cg3018002
[5] Vrouenraets, S.M., Wit, F.W., Tongeren, J.V., Lange, J.M. Efavirenz: a review. Expert
opinion on pharmacotherapy 8, (2007), 851–871.
[6] Jaydip, B., Dhaval, M., Soniwala, M.M., Cavdan, J. Formulation and optimization of
liquisolid compact for improving the dissolution profile of efavirenz by using DoE approach.
Saudi Pharmaceutical Journal 28 (2020) 737-745. https://doi.org/10.1016/j.jsps.2020.04.016
[7] Kakad, S., and Kshirsagar, S. Nose to brain delivery of Efavirenz nanosuspension for
effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment. Heliyon vol 7,
(2021).